Hikal Ltd
NSE: HIKAL BSE: 524735
₹168.48
(1.53%)
Tue, 31 Mar 2026, 07:57 am
Market Cap20.81B
PE Ratio0
Dividend0.59
Health Technology
Pharmaceuticals: Major
24.5KHikal Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are well covered by earnings (6.3x coverage).
- Dividends after 3 years are expected to be thoroughly covered by earnings (9.1x coverage).
- Hikal's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Hikal's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Hikal's earnings are expected to grow significantly at over 20% yearly.
- Hikal's earnings growth is expected to exceed the India market average.
- Hikal's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Hikal's earnings are expected to exceed the low risk growth rate next year.
- Hikal's net income is expected to increase by more than 50% in 2 years time.
- Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
- An improvement in Hikal's performance (ROE) is expected over the next 3 years.
- Hikal's revenue growth is expected to exceed the India market average.
- Cash flow for Hikal is expected to increase but not above the 50% threshold in 2 years time.
- Hikal is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- Hikal's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Hikal's revenue is expected to grow by 11.5% yearly, however this is not considered high growth (20% yearly).
health
- Hikal is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Hikal is profitable, therefore cash runway is not a concern.
- Hikal is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (36.3%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1.2x debt.
- Hikal's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (103.7% vs 78% today).
- Interest payments on debt are well covered by earnings (EBIT is 4.5x coverage).
- Hikal's level of debt (78%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Hikal board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Sameer's remuneration is higher than average for companies of similar size in India.
- Sameer's compensation has increased by more than 20% in the past year whilst earnings fell less than 20%.
misc
- Hikal is covered by less than 3 analysts.
- Hikal has significant price volatility in the past 3 months.
past
- Hikal's year on year earnings growth rate has been positive over the past 5 years.
- Hikal used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Hikal has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Hikal's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Hikal has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Hikal's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- Hikal is good value based on expected growth next year.
- Hikal is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Hikal's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Hikal's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Hikal is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Hikal is overvalued based on earnings compared to the India market.
- HIKAL underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- HIKAL underperformed the Market in India which returned -14.5% over the past year.
- NSEI:HIKAL is up 5.1% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:HIKAL is up 5.1% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800